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Studies were conducted to elucidate co-receptor spectrum and function of the inflammatory receptor, CMKLR1/ChemR23, which was recently
identified as the receptor for the cystatin-like chemoattractant, TIG2, also named chemerin. An infection model was applied based on stably
transfected NP-2.CD4 host cells expressing various co-receptor constructs and exposed to panels of HIV-1, HIV-2 and SIV primary isolates. In a
panel of 27 HIV-1 isolates tested, 12 isolates could use CMKLR1/ChemR23. As expected from a relatively high sequence homology with the
extracellular domains of CCR3, HIV-1 isolates showing R3 tropism were particularly efficient in using CMKLR1/ChemR23. In addition, 5 out of
7 HIV-2 isolates and 13 out of 15 SIV (SMM-3 origin) used CMKLR1/ChemR23, in accordance with the previously documented ability of these
isolates to use several co-receptors. In order to define important extracellular epitopes for the viral interaction, a hybrid receptor model was
applied. This was based on the fact that the rat receptor, although structurally very similar to the human orthologue, was inefficient as viral co-
receptor. When the rat receptor was “humanized” to include regions unique to the human receptor (N-terminus or second extracellular loop),
exposure to HIV-1, HIV-2 and SIV isolates resulted in infection. The relative importance of the two critical receptor regions differed between HIV-
1/HIV-2 on the one hand and SIV on the other. The results strongly support that the chemerin receptor, in the presence of CD4, functions as a
“minor co-receptor” promoting infection by these classes of viruses.
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Human immunodeficiency virus 1 and 2 (HIV-1 and -2) and
simian immunodeficiency virus (SIV) require the CD4 receptor
(Dalgleish et al., 1984; Klatzmann et al., 1984) together with
particular seven-transmembrane G-protein coupled receptors
(GPCRs) for entry into, and infection of, human immune cells.
The chemokine receptors, CXCR4 and CCR5, are the major co-
receptors for HIV and SIV. HIV uses both (Choe et al., 1996;
Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996; Feng
et al., 1996) as major co-receptors whereas CCR5 is the main⁎ Corresponding author. Fax: +46 46 2220568.
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doi:10.1016/j.virol.2006.07.010co-receptor for SIV (Marcon et al., 1997). Besides the major co-
receptors, a large number of additional, so-called minor, co-
receptors have been described that mediate viral entry “in vitro”
(Edinger et al., 1997). ChemR23, first mentioned under the
name of chemoattractant-like receptor 1 (CMKLR1) (Gantz et
al., 1996), is primarily expressed in dendritic cells and
macrophages, and has been proposed to function as a minor
co-receptor promoting infection by select HIV and SIV isolates
(Samson et al., 1998). Upon the recent identification of the
endogenous receptor ligand as chemerin, the receptor is now
also described as “the chemerin receptor” (Wittamer et al.,
2003). Expression of the receptor mRNA has also been detected
in trophoblast cells from early placentas (Mognetti et al., 2000)
as well as in human fetal and simian adult astrocytes (Croitoru-
Lamoury et al., 2003).
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of the importance of the chemerin receptor as a co-receptor for
HIV-1, HIV-2 and SIV using an infection model with primary
isolates. Earlier work from our laboratory, forming part of this
study, was performed before CMKLR1 was identified as the
chemerin receptor. For reason of consistency, the designation
CMKLR1 will therefore be used throughout the present study as
a synonym for the chemerin receptor. The human glioma cell
line, NP-2, was chosen as host cell line for recombinant receptor
expression since it lacks endogenous co-receptors, except in the
case of Bonzo/CXCR6/STRL33 for which low mRNA expres-
sion has been detected (Soda et al., 1999). The domains
important for the virus interaction with the chemerin receptor
were mapped by the use of recombinant hybrid receptor
constructs.
Results
Stable expression of recombinant receptors in NP-2.CD4 cells
Flow cytometric studies were performed on NP-2 cells stably
expressing the CD4 receptor, alone or in combination with the
following receptors: CCR5, CXCR4, CCR3, FC-4b (a chimera
where the N-terminal region originates from CXCR4 and the C-
terminal region originates from CCR5) (Antonsson et al., 2003),
hCMKLR1, rCMKLR1, hCMKLR1-EGFP, rCMKLR1-EGFP,
rCMKLR1.hECL2-EGFP or rCMKLR1.hNterm-EGFP. The
receptor mAbs and isotype control antibodies that were used
appear in Table 1. An equally high expression level of CD4
(data not shown) was confirmed for all cell lines. Other
transfected receptors were also expressed at high level (Figs.
1A–D), except CCR3 that showed low expression (Fig. 1E).
However, expression was enough for its use as positive control
in the ELISA assays following the infection experiments with
CCR3-using (i.e., R3) isolates. Although hCMKLR1 and
rCMKLR1 show 86% sequence identity (Fig. 2), the
hCMKLR1 antibody was not specific for rCMKLR1,
rCMKLR1-EGFP or rCMKLR1.hECL2-EGFP and, hence,
expression of these receptors could not be confirmed by flow
cytometry. Instead, localization at the rCMKLR1-EGFP andTable 1
Antibodies used for the cytometric analysis
Receptor Primary
mAb
Secondary
mAb
Isotype primary
mAb
Isotype secondary
mAb
CD4 CD4-RPE IgG1-RPE
CCR5 CCR5-
RPE
IgG2Ak-RPE
CXCR4 5/5B5 F(ab′)2-RPE 7B1-IgG2A F(ab′)2-RPE
FC-4b 5/5B5 F(ab′)2-RPE 7B1-IgG2A F(ab′)2-RPE
CCR3 CCR3-
RPE
IgG2A-RPE
hCMKLR1 hCMKLR1 F(ab′)2-RPE IgG3 F(ab′)2-RPE
The 5/5B5 and 7B1 antibodies were generated in house (Antonsson et al., 2003;
Pettersson et al., 2000). The hCMKLR1, IgG3, CCR3 and IgG2A antibodies
were purchased from R&D Systems, whereas CD4, IgG1, CCR5 and IgG2Aκ,
were bought from PharMingen-BD Biosciences. Goat anti-mouse immunoglo-
bulin F(ab′)2-RPE was purchased from Daco Cytomation.rCMKLR1.hECL2-EGFP constructs to the cell surface was
confirmed by confocal microscopy (Fig. 3). Since the
hCMKLR1 mAb recognized rCMKLR1.hNterm-EGFP, it
indicates that it is specific for the N-terminus. Native NP-2
cells were used as negative controls in the flow cytometric
analysis (data not shown).
Characterization of hCMKLR1 as a co-receptor
As a general characterization of hCMKLR1 as co-receptor
for HIV-1, 15 isolates of different genetic subtypes (A, B, C, D,
E, F) were tested. Only 3 isolates, of subtype D, were shown to
infect the test cells (Table 2). Since all HIV-1 isolates use either,
or both, of the major co-receptors, CCR5 and CXCR4, and as a
further control for the infectivity of the various isolates tested,
infection experiments were in the entire study carried out with
cells expressing CCR5 and CXCR4, respectively. Table 2 also
shows that three positive isolates, in addition, used the hybrid
receptor, FC-4b, for infection. Cells expressing CD4 alone were
always negative.
The sequence similarity between hCMKLR1 and some
structurally related, more well-established, co-receptors was
elucidated by amino acid alignments of the extracellular
receptor domains (Fig. 4). The highest sequence similarity
was found for CCR3, particularly within the first cellular loop
(ECL1 in Fig. 3). Against this background, 12 isolates of the R3
phenotype (clade B) were tested for their ability to infect cells
expressing hCMKLR1. The isolates have been further char-
acterized in previous studies (Karlsson et al., 2003, 2004). As
many as nine of these isolates used hCMKLR1 for infection
(Table 3). All isolates also used the hybrid FC-4b receptor
efficiently (not included in Table 3). As before, cells expressing
CD4 alone were all negative.
hCMKLR1 was also tested for its ability to support infection
of CD4+ cells with HIV-2. Five isolates out of 7 tested utilized
this receptor (Table 4). In all cases tested, FC-4b also supported
HIV-2 infection.
SIVsm (strain SMM-3), originally isolated from a naturally
infected sooty mangabey monkey, and 14 sequential SIV
isolates from seven cynomolgus macaques inoculated with this
isolate, were used to test the SIV usage of hCMKLR1. The
SIVsm/SMM-3 strain, as well as 14 of the sequential isolates,
used hCMKLR1 (Table 5). As expected from previous studies
(Bron et al., 1997; Chen et al., 1997; Edinger et al., 1997; Hill et
al., 1997; Kirchhoff et al., 1997; Marcon et al., 1997), all
isolates tested were positive for CCR5. In contrast to the case of
HIV-2, SIV showed little or no usage of the CCR5/CXCR4
receptor chimera, FC-4b. All SIV isolates where amplified in
human PBMCs. In a separate study, some isolates were
amplified also in monkey PBMCs, which gave the same results.
Mapping the virus-binding domain of CMKLR1
Although the human and rat orthologues, rCMKLR1 and
hCMKLR1, show 86% overall identity at amino acid level (Fig.
2), only the human variant acted as co-receptor for most isolates
tested (Table 6). The largest sequence differences were detected
Fig. 1. (A–E) Flow cytometric analysis of stable expression of receptors in NP-2 cells. Each cell line was stained for the CD4 receptor (data not shown) and CCR5,
CXCR4, CCR3, FC4-b, hCMKLR1, rCMKLR1, hCMKLR1-EGFP, rCMKLR1.hNterm-EGFP, rCMKLR1-EGFP and rCMKLR1.hECL2-RGFP, respectively.
Dotted-line histograms represent cells stained with isotype control antibodies whereas continuous-line histograms indicate staining with specific receptor antibodies.
Non-transfected NP-2 cells were used as negative control for all antibodies tested.
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Fig. 2. Amino acid alignment of rCMKLR1 (accession no. AJ002745) and hCMKLR1 (accession no. U79526 for hCMKLR1a, having two additional amino acids as
indicated within parenthesis, and U79527 for hCMKLR1b). The alignment was performed using the Clustal X program. Shaded boxes represent regions of identity
between species. The human N-terminus and extracellular loops were assessed using the program TMHMM 2.0 and indicated by horizontal lines.
9U.E.A. Mårtensson et al. / Virology 355 (2006) 6–17in the N-terminus and in the second extracellular loop (Fig. 2).
In order to find out whether a particular region of hCMKLR1
was important for virus entry, we exchanged either the second
extracellular loop or the N-terminus of rCMKLR1 for the
corresponding human sequences. In the absence of a mAb
recognizing rCMKLR1, we tagged the constructs with EGFP in
order to confirm surface expression (Fig. 3).
All isolates that were positive with hCMKLR1 and at the
same time negative with wild-type rCMKLR1 (Table 6) were
also tested on the chimeras. The results from quantitative data
with select isolates in which the hCMKLR1 usage was
particularly efficient are shown in Fig. 5.
Taken together, rCMKLR1 did only support infection by
some of the HIV-1 isolates. “Humanizing” the rat receptor by
exchanging either the N-terminus or the second extracellular
loop increased the infectibility with HIV-1, to a varying degree
for the two extracellular regions. Both regions seem to be
important also for promoting infection with HIV-2 isolates. On
the other hand, infection experiments with the SIV isolates
indicated that the second extracellular loop was the primary
domain recognized for co-receptor function.
Discussion
As part of a longstanding interest in certain inflamma-
tory-type, functionally unknown (so-called “orphan”)GPCRs, we have devoted our interest to various species
variants of a receptor which has provisionally been
designated CMKLR1—the first name for the human receptor
(Gantz et al., 1996). It has later been described as CMKRL3
in rat (Owman et al., 1996), DEZ in mouse (Methner et al.,
1997), ChemR23 again in human (Samson et al., 1998) and
also listed as Gpcr27 in GPCR databases. Although being
an orphan, the receptor arose particular interest when it was
indicated that the human variant might function as another
so-called minor co-receptor (along with the major co-
receptors, CCR5 and/or CXCR4), promoting entry of select
HIV-1 and SIV isolates into immune cells (Samson et al.,
1998). In the course of our ongoing project, we have
characterized the promoter function of the mouse receptor
orthologue (mCMKLR1) and have provided evidence for the
existence of a second, previously unknown, splice variant of
the receptor gene (Mårtensson et al., 2004, 2005). By the
recent identification of the natural ligand as a proinflamma-
tory mediator called chemerin (Wittamer et al., 2003),
previously known as TIG2 (Nagpal et al., 1997), it will now
be possible to explore also the physiological relevance of
this receptor.
In the light of the accumulated interest in CMKLR1, we have
in the present study further elucidated its viral co-receptor
spectrum and function. Among 10 HIV-1 isolates of various
subtypes previously tested by Samson et al. (1998), only one
Fig. 3. Cell membrane localization of receptors using confocal microscopy. (A) NP-2.CD4 cell lines expressing receptors fused to EGFP in the C terminal were fixed
on a multi-well chamber microscopy slide. (B) The cell lines were also stained for CD4 receptor expression. (C) Overlay of green and red fluorescence confirms
membrane localization.
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the present study, 12 isolates were positive. The observation that
they all belonged to either clade B or D may simply be due to
the fact that the panel included fewer isolates of other genetic
subtypes (A, C, E and F).
When comparing the amino acid sequence of the extra-
cellular domains (i.e., the putative virus-binding regions) of
well-known minor co-receptors, it was found that CMKLR1
mostly resembled CCR3. For this reason, we chose to include
12 well-characterized R3 isolates (Karlsson et al., 2003, 2004)
among the abovementioned panel of 27 HIV-1 isolates. As
could be expected, the majority of the R3 isolates turned out to
be positive also for CMKLR1.
HIV-2 seems to use CMKLR1 much more efficiently than
HIV-1 for cellular entry. Out of seven tested isolates, five were
positive. In contrast, three HIV-2 isolates previously tested
using a cell−cell fusion assay (Samson et al., 1998), rather
than the present infection model, were all negative. The
discrepancy in results may be explained by the way isolates
were selected for testing, and/or differences in assay
techniques. Our findings are in line with the general notion
that HIV-2 is more promiscuous in utilizing a broader
repertoire of various cellular co-receptors than HIV-1 (Bron
et al., 1997; McKnight et al., 1998). The ability of HIV-2 to
enter CD4− cells (Reeves et al., 1999), suggests a more
flexible structure of the envelope glycoprotein (Reeves and
Schulz, 1997), which may confirm this statement.Although SIV is of non-human origin, the structure is very
similar to HIV-1 and HIV-2 in both genetic sequence and
biological aspects (Desrosiers and Ringler, 1989). SIV has
therefore become a useful model for studies of co-receptor
interactions, particularly since the virus is less restrictive in its
co-receptor spectrum. It has, therefore, conveniently been used
to screen for co-receptor function in more general terms. In both
the present study and in that by Samson et al. (1998), a large
number of SIV isolates of varying origin efficiently utilized
CMKLR1/ChemR23 for cellular entry. This further supports
that CMKLR1 (i.e., the chemerin receptor) is a potent mediator
of immunodeficiency virus entry. In accordance with this,
CMKLR1 is expressed in dendritic cells and macrophages,
which are well-known targets for HIV/SIV. However, the
receptor also has a more widespread expression, including
astrocytes, chondrocytes, placenta, microglia and maybe also
(depending on species) liver, lung, parathyroid gland and
thymus (Croitoru-Lamoury et al., 2003; Methner et al., 1997;
Mognetti et al., 2000; Mårtensson et al., 2004; Owman et al.,
1996). The relevance of these multiple expression sites when it
comes to viral infection and inflammation has to await future
experiments.
The FC-4b receptor chimera, which is a hybrid between
CCR5 and CXCR4, has proved useful in elucidating certain
evolutionary aspects of HIV-1 co-receptor use. It was therefore
included in the present co-receptor characterization, but it did
not reveal any further distinct feature of CMKLR1/ChemR23
Table 2
Co-receptor function of hCMKLR1 expressed in NP-2. CD4 cells as analyzed
by infection with HIV-1 isolates of different subtypes
Virus
isolate
Genetic
subtype
Infectious dose
(ng/ml)
HIV-1 p24 antigen production in
supernatants of cells expressing:
CCR5 CXCR4 FC-4b hCMKLR1
93UG-086 D 2 +++ +++ +++ ++
5 +++ +++ +++ ++
10 +++ +++ +++ ++
92UG-053 D 2 − +++ +++ +
5 − +++ +++ +
10 − +++ +++ ++
92UG-021 D 2 − + − +
10 − +++ ++ ++
20 − +++ +++ +++
94UG-118 D 2 +++ − − −
5 +++ − − −
10 +++ − − −
92UG-005 D 2 +++ ++ − +
5 +++ + − −
10 +++ ++ − −
92UG-001 D 2 − +++ − −
5 − +++ − −
10 − +++ − −
94UG-117 D 2 − +++ − −
5 − +++ − −
10 − +++ − −
92UG-024 D 2 − + − −
10 − +++ + −
20 − +++ + −
93UG-070 D 2 − +++ +++ −
10 − +++ +++ −
20 − +++ +++ −
92UG-037 A 2 +++ − − −
10 +++ − + −
20 +++ − + −
92BR-020 B 2 +++ − − −
5 +++ − + −
10 +++ + + −
92BR-025 C 2 +++ − − −
3 +++ − − −
93BR-019 B 2 +++ +++ − −
5 +++ ++ +++ −
10 +++ +++ +++ −
93BR-029 F 2 +++ − − −
5 +++ − + −
10 +++ − + −
92TH-019 E 2 + − − −
NP-2.CD4-CCR5, -CXCR4, -FC-4b and -hCMKLR1 cells were infected with
above shown concentrations of virus. The ability to use the receptors is
presented as the average of absorbance from triplicate wells obtained in enzyme-
linked immunosorbent assay (ELISA) (absorbance of uninfected cells is
subtracted). −, p24 antigen negative (absorbance < 0.3); +, p24 antigen positive
(absorbance 0.3–0.9); ++, p24 antigen positive (absorbance 1.0–1.9); +++, p24
antigen positive (absorbance > 2.0). Parental NP-2.CD4 cells were included in
each experiment and were negative for HIV-1 p24 antigen.
11U.E.A. Mårtensson et al. / Virology 355 (2006) 6–17co-receptor function. The reason for the broad viral usage of
FC-4b may simply reflect the fact that the hybrid receptor is
composed of important epitopes from both CCR5 and CXCR4.
The general picture of the structural requirements for co-
receptor function indicates that several extracellular epitopes are
involved in virus entry (Alkhatib et al., 1997; Atchison et al.,
1996; Brelot et al., 1997; Doranz et al., 1997; Wittamer et al.,2003; Zhou et al., 2001). Although there is a high sequence
similarity between the human and rat orthologues, the rat
receptor was presently shown to be inefficient as a viral co-
receptor. Since the highest sequence differences between the rat
and human receptors are found in the N-terminus and the
second extracellular loop, these regions were interchanged,
resulting in a “humanized” rat receptor equipped with the
human N-terminus or second extracellular loop. The hybrids
were used to elucidate the isolate preference for either of these
receptor epitopes.
While both HIV-1 and HIV-2 could use either the N-terminus
or the second extracellular loop of CMKLR1, SIV seemed to
prefer the second extracellular loop of the receptor for infection.
The ability of HIV-2 to use alternative epitopes for viral entry
agrees well with the more promiscuous nature of this virus. The
sequential SIV isolates tested with the hybrid receptors all
displayed a high dependence of the second extracellular loop.
In conclusion, the results support the evidence that the
chemerin receptor can function as a minor co-receptor for select
HIV-1 isolates, as well as more generally for HIV-2 and SIV
isolates. Among certain better-characterized co-receptors, the
HIV-1 co-receptor function of the chemerin receptor resembles
that of CCR3. Using a “humanized” hybrid rat chemerin
receptor as model, it was shown that the major determinants for
HIV-1 and HIV-2 interaction with the receptor reside to a
varying degree in the N-terminus and second extracellular loop,
whereas the viral interaction in the case of SIV primarily
involves the second extracellular loop.
Materials and methods
Virus isolates
The HIV-1 isolates 92UG021, 92UG024, 92UG037,
93UG070, 92BR020, 92BR025, 93BR019, 93BR029 and
92TH019 were obtained from the WHO Network for HIV
Isolation and Characterization (Rubsamen-Waigmann et al.,
1994; WHO, 1994). Other HIV-1 isolates as well as HIV-2
isolates were previously characterized in separate studies
(Bjorndal et al., 1997; Karlsson et al., 2003, 2004; Morner
et al., 1999; WHO, 1994). The primarily SIV isolates were
isolated from cynomolgus macaques, inoculated with SIVsm
(strain SMM-3 from P. Fultz and H. Mclure, Yerkes
Regional Primate Research Center, Atlanta, GA, USA).
Strain SMM-3 was originally isolated from a naturally
infected sooty mangabey. 56:3, 59:3, C2, C44, C68, C73
and B174 represent the name of the inoculated cynomolgus
macaques whereas the figures following the colon (56:3:56)
describe the day post-infection that blood samples were
collected for virus isolation.
Virus stocks were prepared by infection of phytohemagglu-
tinin (PHA)-stimulated peripheral blood mononuclear cells
(PBMCs) mixed from two blood donors. The donor PBMCs
were isolated by separation of buffy coats on Ficoll gradient
(Pharmacia) in RPMI-1640+Glutamax I culture medium,
supplemented with 10% fetal calf serum (FCS) and 0.5%
penicillin/streptomycin. Pooled PBMCs (7×106) were infected
Fig. 4. Alignments of amino acid sequences from the extracellular regions of various co-receptors. The alignments were performed using the Clustal X program.
Shaded boxes represent regions of identity between co-receptors. The extracellular regions were assessed using the program TMHMM 2.0.
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of interleukin 2 (IL-2, Amersham Biosciences), 2 μg/ml
polybrene (Sigma), 50 U/ml penicillin and 50 μg/ml strepto-
mycin. Cell-free supernatants were harvested at day 8, 10 and12, assayed for virus antigen content and stored at −80 °C until
used. HIV-1 was detected by measuring virus p24 antigen in a
p24 ELISA (Vironostika HIV-1 Antigen, Biomérieux). HIV-2
and SIV were detected by measuring virus p26 antigen in an
Table 3
Co-receptor function of hCMKLR1 expressed in NP-2.CD4 cells as analyzed by
infection with CCR3-using HIV-1 isolates
Virus
isolate
Infectious dose
(ng/ml)
HIV-1 p24 antigen
production in supernatants of
cells expressing:
CCR3 hCMKLR1
3609:5186 2 +++ +++
5 +++ +++
10 +++ +++
778:975 2 +++ +
5 +++ +
10 +++ ++
2289:5103 2 +++ −
5 +++ +
10 +++ ++
553:1004 2 +++ −
5 +++ +
1679:2129 2 +++ −
5 +++ +
10 +++ +
1679:5594 2 +++ −
5 +++ +
10 +++ +
1991:6750 2 +++ −
5 +++ +
10 +++ +
230:7279 2 +++ −
5 +++ −
7 +++ +
958:8567 2 +++ −
5 +++ −
10 +++ +
446:744 2 +++ −
5 +++ −
10 +++ −
1865:3017 2 +++ −
5 +++ −
10 +++ −
1865:3305 2 +++ −
5 +++ −
10 +++ −
NP-2.CD4-CCR3 and -hCMKLR1 cells were infected with above shown
concentrations of virus. To confirm the infectivity of the isolates used, they were
tested on NP-2.CD4-CCR5 and -CXCR4 cells. All isolates used these co-
receptors to a variable extent (cf. Karlsson et al., 2003, 2004). The ability to use
the receptors is presented as the average of absorbance from triplicate wells
obtained in enzyme-linked immunosorbent assay (ELISA) (absorbance of
uninfected cells is subtracted). −, p24 antigen negative (absorbance < 0.3); +,
p24 antigen positive (absorbance 0.3–0.9); ++, p24 antigen positive (absorbance
1.0–1.9); +++, p24 antigen positive (absorbance > 2.0). Parental NP-2.CD4
cells were included in each experiment and were negative for HIV-1 p24
antigen.
Table 4
Co-receptor function of hCMKLR1 expressed in NP-2. CD4 cells and analyzed
by HIV-2 isolates
Virus
isolate
Infectious dose
(ng/ml)
HIV-2 p26 antigen
production in supernatants
of cells expressing:
FC-4b hCMKLR1
1812 1.5 Pos Pos
1010 1.1 Pos Pos
1816 1.5 Pos Pos
1808 1.5 Pos Pos
1654 1.5 NTa Pos
6669 1.5 Pos Neg
1653 1.5 NT Neg
NP-2.CD4-FC4-b and -hCMKLR1 cells were infected with different HIV-2
isolates. To confirm the infectivity of the isolates used, they were tested on NP-2.
CD4-CCR5 and -CXCR4 cells. All isolates used these co-receptors to a variable
extent (cf. Morner et al., 1999). The ability to use the receptors is presented as
absorbance obtained in enzyme-linked immunosorbent assay (ELISA). Defini-
tion of Pos and Neg, see Materials and methods ( Virus isolates).
a NT, not tested.
Table 5
Co-receptor function of hCMKLR1 expressed in NP-2. CD4 cells as analyzed
by infection with SIV isolates
Virus
isolate
Infectious dose
(ng/ml)
HIV-1 p26 antigen production in
supernatants of cells expressing:
CCR5 FC-4b hCMKLR1
SIVsm 10 Pos Pos Pos
56:3:56 2 Pos Neg Pos
56:3:91 2 Pos Neg Pos
59:3:56 6 Pos Pos Pos
59:3:91 6 Pos Neg Pos
59:3:730 6 Pos Pos Pos
C2:264 3 Pos NTa Neg
C2:498 4 Pos NT Neg
C44:90 10 Pos Pos Pos
C44:365 10 Pos Neg Pos
C44:810 10 Pos Neg Pos
C68:90 10 Pos Neg Pos
C68:1590 10 Pos Neg Pos
C73:540 10 Pos Neg Pos
B174:14 10 Pos Pos Pos
NP-2.CD4-CCR5, -FC-4b, and -hCMKLR1 cells were infected with above
shown concentrations of virus. The ability to use the receptors is presented as the
average of absorbance from triplicate wells obtained in enzyme-linked
immunosorbent assay (ELISA). Definition of Pos and Neg, see Materials and
methods (Virus isolates).
a NT, not tested.
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analyzing virus reverse transcriptase activity using Cavidi HS-
kit Lenti RT (Cavidi Tech AB). The p26 ELISA does not allow
for quantitative analysis. Instead, results in the Tables are
arbitrarily expressed as positive (Pos) or negative (Neg). Pos is
defined as the absorbance level exceeding three times above
background (absorbance value >0.3). Presently, background is
defined as the absorbance measured in non-infected cells (i.e.,
cells expressing co-receptor but receiving only vehicle) or incells without co-receptor, expressing CD4 only, receiving virus.
Results shown as Neg reflect absorbance level <0.3.
Constructions of human/rat receptor hybrids
The coding regions of human and rat CMKLR1 (hCMKLR1
and rCMKLR1) were amplified from genomic DNA by PCR
using PwoDNApolymerase (RocheDiagnostics) and cloned into
BamHI or EcoRV/NotI sites of the bicistronic vector, pIRESpuro
(Clontech). Constructs were sequenced using the BigDye
Terminator Cycle Sequencing kit (PE Applied Biosystems).
Table 6
Co-receptor function of rat CMKLR1 expressed in NP-2.CD4 cells as analyzed
by infection with HIV-1, HIV-2 and SIV isolates
Virus type Virus isolate Infectious dose
(ng/ml)
p24/p26 antigen
production in supernatants
of cells expressing:
hCMKLR1 rCMKLR1
HIV-1 3609:5186 a 10 +++ −
UG92021 10 ++ −
UG92053 10 ++ −
2289:5103 10 ++ −
778:975 10 ++ +
UG93086 10 ++ +++
1679:5594 10 + +++
1991:6750 10 + ++
553:1004 5 + ++
HIV-2 1812 a 1.5 Pos Neg
1010 a 1.1 Pos Neg
1654 1.5 Pos Neg
1808 1.5 Pos Neg
1816 1.5 Pos Neg
SIV 59:3:56 a 6 Pos Neg
59:3:91 a 6 Pos Neg
59:3:730 a 6 Pos Neg
56:3:56 2 Pos Neg
56:3:91 2 Pos Neg
C44:90 10 Pos Neg
C44:365 10 Pos Neg
C44:810 10 Pos Neg
C68:90 10 Pos Neg
C68:1590 10 Pos Neg
C73:540 10 Pos Neg
B174:14 10 Pos Neg
SIVsm 10 Pos Neg
NP-2.CD4-hCMKLR1 and -rCMKLR1 cells were infected with the above
shown concentrations of HIV-1, HIV-2 or SIV isolates. NP-2.CD4-CCR5 and
-CXCR4 were used as positive controls. The ability to use the receptors is
presented as the average of absorbance obtained from triplicate wells in enzyme-
linked immunosorbent assay (ELISA) (absorbance of uninfected cells is
subtracted). −, p24 antigen negative (absorbance<0.3); +, p24 antigen positive
(absorbance 0.3–0.9); ++, p24 antigen positive (1.0–1.9); +++, p24 antigen
positive (absorbance > 2.0). Definition of Pos and Neg, see Materials and
methods (Virus isolates).
a Isolates tested on human/rat CMKLR1 hybrids as shown in Fig. 5.
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frame to the C-terminus of hCMKLR1 (hCMKLR1-EGFP)
and rCMKLR1 (rCMKLR1-EGFP), respectively, using a
stepwise PCR procedure according to a modified protocol
(Olde et al., 1998) of the single-overlap extension method
(Lefebvre et al., 1995). The same method was used to
replace the N-terminus and the second extracellular loop of
the rCMKLR1-EGFP with the corresponding human
sequences, resulting in the chimera rCMKLR1.hNterm-
EGFP and rCMKLR1.hECL2-EGFP. Final constructs were
subcloned into the EcoRV/NotI sites of pIRESpuro and their
identity confirmed by sequencing.
Stable expression of recombinant receptors
The human glioma cell line, NP-2, with and without stably
expressed CD4 (NP-2.CD4), was kindly provided by Dr. HirooHoshino (Gunma University School of Medicine, Japan). The
cells were grown in Eagle's minimum essential medium
(EMEM) (Sigma) supplemented with 10% fetal bovine serum
(FBS), 1% glutamax (Invitrogen), 50 U/ml penicillin, 50 μg/ml
streptomycin and 0.5 mg/ml geneticin (Invitrogen) at 37 °C in
7% CO2. NP-2.CD4 cells were stably transfected with either of
the following receptor cDNAs: CCR5, CXCR4, FC-4b (a
chimera between CXCR4 and CCR5), CCR3, hCMKLR1,
rCMKLR1, hCMKLR1-EGFP, rCMKLR1-EGFP, rCMKLR1.
hECL2-EGFP and rCMKLR1.hNterm-EGFP. The respective
coding sequences (all verified by sequencing) were cloned into
the pIRESpuro vector (Clontech). The day before transfection,
8×105 NP-2.CD4 cells were seeded in 10-cm dishes, and 4 μg
receptor plasmid was transfected using Lipofectamine (Invi-
trogen). Two days after transfection, cells were transferred to
15-cm dishes and selected for 3 weeks in media supplemented
with 0.5 μg/ml puromycin (Sigma) for stable monoclonal
receptor expression.
Virus infection of receptor-expressing NP-2.CD4 cells
Two days before infection, 4×103 cells/well were seeded
into 48-well plates using medium without antibiotics. At the
time of infection, medium was removed and virus added to
triplicate wells in 200 μl medium containing polybrene
(2 μg/ml). Two hours after infection, medium with polybrene
was added to a total volume of 500 μl/well. After overnight
incubation, cells were washed 3 times in 1 ml PBS (PBS
Dulbecco's) (Life technologies), and 1 ml fresh medium
without polybrene was added to each well. Twelve days after
infection, medium was sampled from each well for detection
of viral antigen. HIV-1 and HIV-2/SIV infection was
monitored with ELISA as described above. Cells were also
evaluated microscopically for syncytia formation.
Flow cytometric analysis
1×106 cells per sample were washed in washing buffer (PBS
without Ca2+, Mg2+ and sodium bicarbonate+0.5% milk
powder+0.003% sodium azid) (Kebo) and suspended in
100 μl washing buffer containing 0.08–2 μg/μl anti-receptor
monoclonal antibody (mAb) and corresponding isotype control
(Table 1). R-phycoerythrin conjugated to the antibody was used
for detection. The cells were incubated for 30 min at 4 °C,
washed twice and re-suspended in 500 μl washing buffer for
analysis. In case a secondary antibody was needed for detection,
cells were incubated for another 30 min at 4 °C in 100 μl
washing buffer containing 25 ng/μl R-phycoerythrin conjugated
goat anti-mouse immunoglobulin F(ab′)2, whereafter cells were
washed and re-suspended as above, followed by analysis in a
Becton-Dickinson FACS Calibur flow cytometer using the
CellQuest software.
Confocal microscopy
NP-2.CD4 cells stably expressing hCMKLR1-EGFP,
rCMKLR1-EGFP, rCMKLR1.hECL2-EGFP or rCMKLR1.hN-
Fig. 5. HIV-1, HIV-2 and SIV infection of NP-2 cells expressing CD4 alone or in combination with either hCMKLR1, hCMKLR1-EGFP, rCMKLR1-EGFP,
rCMKLR1.hNterm-EGFP and rCMKLR1.hECL2-EGFP. (A) Infection with a HIV-1 isolate, strongly positive for hCMKLR1 (3609:5186 [10 ng/ml] in Table 3). The
level of infection was estimated by measuring the HIV-1 p24 content in the cell medium 12 day post-infection. (B) Infection with two positive HIV-2 isolates (1812
[2 ng/ml] and 10101 [2 ng/ml], Table 4). The degree of infection was detected in cell culture supernatants 12 day post-infection with p26 ELISA. (C) Infection with
three positive sequential SIV isolates (59:3:56 [10 ng/ml], 59:3:91 [10 ng/ml], 59:3:730 [10 ng/ml], Table 5). Degree of infection was assayed as in panel B.
Background signal from non-infected cells has been subtracted. Bars represent means+SD from triplicates. The various recombinant test receptors and receptor
hybrids are depicted schematically.
15U.E.A. Mårtensson et al. / Virology 355 (2006) 6–17term-EGFP were grown on multi-well chamber slides. At 40%
confluency, cells were washed 3 times in PBS (withoutMg2+ and
Ca2+)+0.5% BSA and fixed in 4% formaldehyde (Sigma) for
15 min at room temperature. Cells were blocked in PBS+2%
FBS for 20 min at room temperature and stained with R-
phycoerythrin conjugated anti-CD4 mAb or isotype control for
60 min at 4 °C. After 3 times' washing in PBS+0.5% BSA, cellswere mounted in 2.5% PVA-DABCO (Sigma) and examined by
confocal microscopy (Zeiss LSM510, Göttingen, Germany).
Data analysis
Statistical errors are shown as standard deviations (SD).
Sequence alignments were carried out using the Clustal X
16 U.E.A. Mårtensson et al. / Virology 355 (2006) 6–17program and receptor transmembrane predictions to determine
the N-terminus and extracellular loops were made using the
TMHMM 2.0 program (Krogh et al., 2001).
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